

# Revumenib (REVUFORJ) in Acute Leukemia

## Criteria for Use

### February 2026

VA Pharmacy Benefits Management Services and National Formulary Committee

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

### Exclusion Criteria

If ANY of the following are selected, the patient will NOT meet criteria for revumenib.

- Presence of 11q23 partial tandem duplication (PTD)
- QTcF > 450 msec<sup>1</sup>
- Unmanageable drug-drug interaction<sup>2</sup>
- Pregnancy
- Lactating

<sup>1</sup>If concomitant use of QTc prolonging drugs is unavoidable, monitor patients more frequently for QTc interval prolongation

<sup>2</sup> If concomitant strong CYP3A4 inhibitors are necessary, reduce revumenib dose, as recommended

### Inclusion Criteria

One of the following criteria must be selected to meet criteria.

- Relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene (*KMT2A*) rearrangement; includes acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), and mixed-phenotype acute leukemia (MPAL)<sup>1</sup>
- Relapsed or refractory acute myeloid leukemia with NPM1-mutation

<sup>1</sup>Acute leukemia that is unresponsive to the most recent salvage therapy or persists despite intensive induction chemotherapy.

### Additional Inclusion Criteria

All the following must be fulfilled:

- Care is provided by a VA/VA Community Care hematology/oncology provider
- Eastern Cooperative Oncology Group (ECOG) performance status of 0–2
- Goals of care and role of Palliative Care consult have been discussed and documented
- White blood cell count less than  $25 \times 10^9/L$  before starting treatment due to risk of differentiation syndrome

### Additional Inclusion Criteria

If applicable:

- For females who can become pregnant: Pregnancy must be excluded prior to receiving revumenib.
- For females who can become pregnant and males with partners who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy and for 4 months after stopping treatment.

### Other Justification

\_\_\_\_\_